Mizoribine synergistically inhibits osteoclastogenesis in combination with methotrexate

Methotrexate (MTX) is most accepted and potent disease modifying anti-rheumatic drug (DMARD), is also reported to be effective in combination therapy with another drug. In this study, we investigated synergistic effects of mizoribine (MZR) and MTX on in vitro osteoclastogenesis. MZR dose-dependently...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Pharmacological Sciences 2004, Vol.94 (suppl.2), p.188-188
Main Authors: Asako Honda, Toshio Kaneda, Yoshie Kawagishi, Yuki Fujii, Akihiro Muto, Tadashi Yoshida
Format: Article
Language:Japanese
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methotrexate (MTX) is most accepted and potent disease modifying anti-rheumatic drug (DMARD), is also reported to be effective in combination therapy with another drug. In this study, we investigated synergistic effects of mizoribine (MZR) and MTX on in vitro osteoclastogenesis. MZR dose-dependently inhibited M-CSF-induced cell growth and M-CSF/RANKL-induced osteoclastogenesis. Comparing with MZR, the inhibitory effects of MTX were weak and partial at even high dose (>1μM). Synergistic inhibitory effects of MTX and MZR were not observed above experiments. Contrary, VD3-induced osteoclastogenesis containing stromal cells was completely inhibited by low dose MTX (
ISSN:1347-8613